NICE backing for Takeda’s Adcetris for rare lymphoma
Standard of care in untreated systemic anaplastic large cell lymphoma (sALCL) has not changed in several decades
Read More
Tag: sALCL
EU regulators approve Takeda’s Adcetris for sALCL
The decision brings a ‘much needed’ new treatment option to this patient community
Read More
NICE u-turn backs Takeda’s Adcetris for sALCL
Takeda’s Adcetris has now been backed by the National Institute for Health and Care Excellence as an option to treat systemic anaplastic large cell lymphoma (sALCL), a very rare and aggressive cancer of the lymphatic system, on the NHS in England and Wales.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
